Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications
Tsao C, Liaw B, He C, Galsky M, Sfakianos J, Oh W. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Therapeutic Advances In Medical Oncology 2017, 9: 287-298. PMID: 28491148, PMCID: PMC5405995, DOI: 10.1177/1758834016687261.Peer-Reviewed Original ResearchRenal cell cancerCell cancerAnti-programmed cell death protein 1 immune checkpoint inhibitorVascular endothelial growth factor-targeted therapyEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsTreatment of renal cell cancerReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsClinical trial testingCheckpoint inhibitorsKinase inhibitorsLethal malignancyTherapeutic implicationsDisease outcomeDisease biologyTherapyDrug developmentCancerDiseaseInhibitorsNivolumabMalignancyDrug
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply